Furan-2-yl-[4-(3-thiophen-2-yl-1,2,4-thiadiazol-5-yl)piperazin-1-yl]methanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Furan-2-yl-[4-(3-thiophen-2-yl-1,2,4-thiadiazol-5-yl)piperazin-1-yl]methanone
• 化学式: C₁₅H₁₄N₄O₂S₂
• 分子量: 346.4
• InChiKey: MDESRZRSSITAKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  119
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• TREATING CANCER
  申请人：Agency for Science, Technology and Research

  公开号：EP2908843B1

  公开（公告）日：2019-09-04
• EZH2 Cancer Markers
  申请人：Chinnaiyan Arul M.

  公开号：US20090012031A1

  公开（公告）日：2009-01-08

  The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target EZH2 expression in prostate cancer.
• COMPOSITIONS AND METHODS FOR INHIBITING EZH2
  申请人：Chinnaiyan Arul M.

  公开号：US20100222420A1

  公开（公告）日：2010-09-02

  The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target EZH2 expression in prostate cancer.
• METHOD OF TREATING CANCER
  申请人：Agency for Science, Technology and Research

  公开号：US20150258175A1

  公开（公告）日：2015-09-17

  The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.
• US8524682B2
  申请人：——

  公开号：US8524682B2

  公开（公告）日：2013-09-03